Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
bevacizumab
bevacizumab
- Restricted Anti-Neoplastic Formulary
- Restricted VEGF Inhibitors for Macular Degeneration Formulary
- Restricted Avastin --> retinopathy of prematurity in neonates (inpatient/rare), macular degeneration cases(outpatient)
- Restricted Alymsys/Mvasi/Avastin/Avzivi/Zirabev --> is approved for oncology use in outpatient.
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Avastin | SOLUTION, INTRAVENOUS | 25 mg/mL | ||||
| Alymsys | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL | ||||
| Avzivi | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL | ||||
| Mvasi | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL | ||||
| Zirabev | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL |
Last updated: Jun. 28, 2024
- Black Box Warning: GI perforation; wound healing complications
- Chemotherapy:
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Doses for intravitreal use (off-label for macular degeneration and retinopathy of prematurity) are prepared in the IV room.
Avastin inpatient use is approved for retinopathy of prematurity in neonate: Formula Sheet: AVASTIN for intravitreal use in retinopathy of prematurity
Avastin is approved for use in macular degeneration in outpatient setting.
Alymsys, Avzivi, Mvasi & Zirabev will currently not be used for retinopathy of prematurity (ROP) or macular degeneration.
For oncology cases, Alymsys, Avastin, Avzivi, Mvasi, & Zirabev are limited to outpatient cases only. Substitution will be determined by cost/reimbursement of patient case and/or economics at a specific time period for oncology indications
Outpatient Bevacizumab cycle 2+ Rapid infusion protocol available for adults. Outpatient Bevacizumab cycle 2+ Rapid infusion protocol (Adult)
Reviewed: June 22, 2005 (Oncology), 24 April 2018 (Mvasi), 28 January 2020 (Zirabev), Sept 2022 (Alymsys), February 2024 (Avzivi)
Updated: October 25, 2006 (Macular Degeneration), May 10, 2011 (Retinopathy of Prematurity, Pediatric Subcommittee), and October 22, 2019 (Rapid Infusion)
Bevacizumab-maly (Alymsys)
Bevacizumab-tnjn (Avzivi) February 27, 2024